PHA2022 Chap.5 Drug Development and Evidence Translation

Drug Development and Evidence Translation

Drug development is a sequence of decisions under uncertainty rather than a guaranteed pipeline. Target rationale links a biological process to a disease mechanism and proposes an intervention point. Assays test engagement and downstream response.

Candidate properties, selectivity, formulation, exposure and toxicology must support a human study whose starting risk is ethically justified.

Preclinical evidence includes biochemical, cellular, organ, computational and animal models. Each captures some features and omits others. A model is valuable when it predicts a relevant aspect and its boundary is known.

Species differences, artificial endpoints and exposure mismatch can limit translation. Repeating the same assay does not repair a model that lacks the human mechanism.

Early human studies characterise tolerability, pharmacokinetics, pharmacodynamics and dose. Later trials estimate efficacy against a comparator under defined populations and outcomes, while larger programmes expand safety information.

Phase labels are useful shorthand but do not replace the actual design. Some questions overlap, and post-authorisation evidence continues to refine benefit and risk.

Randomisation reduces systematic allocation differences; concealment prevents foreknowledge of allocation; blinding can reduce performance and assessment bias.

A placebo controls expectations and study procedures when ethical, while an active comparator may answer whether the candidate improves on current care. Attrition and missing outcome data can undo advantages if related to treatment or response.

Endpoints must matter.

A surrogate may respond earlier or require fewer participants, but it supports patient benefit only when the relation is validated for the context and intervention. A biomarker can improve while symptoms, function or survival do not.

Composite outcomes can be driven by frequent minor components, so inspect each component and clinical meaning.

Effect estimates need magnitude and uncertainty, not only statistical significance. Relative measures should be paired with absolute outcomes. Prespecified primary outcomes protect against selective emphasis among many measurements.

Subgroup findings need interaction evidence and often replication; significance in one subgroup and not another does not by itself prove the groups differ.

Worked surrogate case: a candidate lowers a laboratory marker substantially in a short trial but the marker is not established as a substitute for patient function. The result supports pharmacological activity and may justify further study.

It does not establish clinical benefit. A later trial should measure a patient-relevant outcome, adequate duration and harms against a defensible comparator.

Generalisability depends on who was included, setting, adherence and co-treatment. Excluding older adults, pregnancy, organ impairment or common comorbidity can improve control but leave important use uncertain.

Approval for a defined indication does not answer off-label populations. Product information, monitoring and post-market studies carry those boundaries forward.

Development revision should follow stop–go questions: Is the target engaged at tolerable exposure? Does the model predict a relevant human mechanism? Is the chosen dose justified? Does the trial isolate efficacy? Is the endpoint meaningful?

Does the benefit outweigh harm for this population? Each no identifies the next evidence need rather than a vague demand for more research.

Safety evidence should separate expected mechanism-based adverse effects, off-target effects and rare idiosyncratic events. Trial duration and sample size limit what can be seen, while post-market reports are sensitive to exposure volume and reporting behaviour.

A signal is a prompt for investigation, not an incidence rate. Compare observed with expected patterns using suitable databases or studies, and update benefit–risk for the relevant indication rather than treating one report as proof or dismissing it as anecdote.

For every phase label, replace the shorthand with the actual population, allocation, comparator, endpoint, duration and safety question being tested.

What this chapter covers

• 01

  preclinical evidence

• 02

  randomisation

• 03

  surrogate endpoint

• 04

  trace a candidate from target rationale through preclinical and clinical evidence while separating safety, efficacy and generalisability

• 05

  Regulatory approval supports a defined benefit–risk decision for an indication; it does not prove universal superiority or absence of rare harm.

Evaluate a surrogate endpoint

Key terms

preclinical evidence

Laboratory and animal evidence used to characterise mechanism, exposure and risk before or alongside human study.

randomisation

Allocation by chance to reduce systematic differences between comparison groups.

surrogate endpoint

A measured substitute intended to predict a patient-relevant outcome.

Drug Development and Evidence Translation FAQ

Exam move

Retrieve the target or decision, trace concentration and time, work one changed case, then write the translational boundary.

Working through Drug Development and Evidence Translation in PHA2022? Sia is AskSia’s AI Pharmacology tutor — ask any PHA2022 Drug Development and Evidence Translation question and get a clear, step-by-step explanation grounded in how PHA2022 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.